Genetic and molecular drivers of scleroderma pathogenesis

Area of Science:

• Immunology
• Genetics
• Fibrosis Research

Background:

• Scleroderma is a complex autoimmune disease characterized by immune dysregulation, vasculopathy, and fibrosis.
• Recent decades of research have revealed key molecular mechanisms underlying scleroderma pathogenesis.
• Genetic studies highlight the immune system's role, identifying interferon and immune regulatory genes associated with scleroderma risk.

Purpose of the Study:

• To elucidate the molecular mechanisms of scleroderma pathogenesis.
• To identify central molecular pathways linking tissue damage to clinical presentation.
• To explore potential therapeutic strategies by translating insights from oncology.

Main Methods:

• Review of biological and genetic association studies.
• Analysis of molecular mechanisms involving immune dysregulation and growth factor signaling.
• Comparative analysis with other diseases and malignancies.

Main Results:

• Interferon and immune regulatory genes are strongly linked to scleroderma risk.
• Growth factor signaling is a central mechanism connecting tissue damage to scleroderma phenotypes.
• Activated growth factor receptors in fibroblasts contribute to excessive collagen production in skin and lungs.

Conclusions:

• The immune system is a fundamental determinant of scleroderma.
• Growth factor signaling pathways are critical in scleroderma pathogenesis and may offer therapeutic targets.
• Therapeutic approaches from oncology targeting overactivated growth factor signaling may be applicable to scleroderma treatment.